- Mesoblast (MSB) enters a trading halt as the company prepares to announce more details in regards to a capital raise
- Trading of MSB shares will be paused until Monday, August 8, or until the company releases further details about the funds it is looking to raise
- Mesoblast have recently focussed activities on its remestemcel-L product candidate across a range of health conditions
- The company finished the June quarter with nearly US$100.45 million (A$144.24 million) in available funding, which was expected to last just over seven quarters
- Shares in Mesoblast last traded at 93 cents each on August 3
Mesoblast (MSB) has entered a trading halt as the company prepares to announce more details in regards to a capital raise.
Trading of MSB shares will be paused until Monday, August 8, or until the company releases further details about the funds it is looking to raise.
Whilst it is not yet known where the money will be directed, Mesoblast has recently focussed its activities on its remestemcel-L product candidate across a range of health conditions.
This includes COVID-19, steroid-refractory graft versus host disease, inflammatory bowel disease, chronic heart failure, and chronic low back pain.
The company finished the June quarter with nearly US$100.45 million (A$144.24 million) in available funding, which was expected to last just over seven quarters.
This included US$40 million, which could be drawn down from existing financing facilities subject to certain milestones.
Shares in Mesoblast last traded at 93 cents each on August 3.